18+ Adults only. We do not sell to anyone under 18. Research compounds are supplied for research use only.
A notebook, a mug of tea and an injection pen on a desk, under the headline Retatrutide side effects and trial doses

Retatrutide side effects and trial doses: what the studies found

Retatrutide is the most searched compound on our site, and the two questions behind most searches are “what are the side effects?” and “what dose did the trials use?”. Large phase 3 results have now been published, so this guide uses them. It reports what the trials found, not what anyone should take.

Retatrutide side effects and trial doses in 60 seconds

  • The phase 3 trials tested 4, 9 and 12 mg once a week. The phase 2 trial reached its doses by stepping up from lower starting doses.
  • In the phase 3 TRIUMPH-1 trial, average weight loss at 80 weeks was 17.6, 23.7 and 25.0 percent on 4, 9 and 12 mg, against 3.9 percent on placebo.
  • The most common side effects were gut related: nausea and diarrhoea. In TRIUMPH-2 (type 2 diabetes), diarrhoea affected 27 to 34 percent and nausea 14 to 28 percent, against 13 and 8 percent on placebo.
  • Low blood pressure and an odd skin sensation called dysesthesia were also more common on retatrutide.

The trials, briefly

  • Phase 2 (2023). 338 adults with obesity received 1, 4, 8 or 12 mg once weekly for 48 weeks, some starting at 2 mg and some at 4 mg. Average weight loss at 12 mg was 24.2 percent at 48 weeks, against 2.1 percent on placebo.
  • TRIUMPH-1 (phase 3, 2026). 2,339 adults with obesity and no diabetes received 4, 9 or 12 mg or placebo once weekly for 80 weeks.
  • TRIUMPH-2 (phase 3, 2026). 1,152 adults with obesity and type 2 diabetes received 4, 9 or 12 mg or placebo once weekly for 80 weeks.

How much weight, at which dose

Two things stand out. The step from 4 mg to 9 mg added far more than the step from 9 mg to 12 mg, so the curve flattens at the top, as it did for semaglutide and tirzepatide (see our guide to GLP-1 dose and weight loss). And people with type 2 diabetes lost less weight at every dose, so a figure from one trial does not transfer to another group.

Side effects reported in the trials

In TRIUMPH-2, the most frequent adverse events were gastrointestinal and were more common on retatrutide than placebo:

  • Diarrhoea: 27 percent (4 mg), 34 percent (9 mg) and 34 percent (12 mg), against 13 percent on placebo.
  • Nausea: 14, 21 and 28 percent, against 8 percent on placebo. Nausea rose with each dose step.
  • Low blood pressure (hypotension): 1, 5 and 6 percent, against under 1 percent.
  • Dysesthesia (an abnormal or unpleasant skin sensation): 4, 6 and 7 percent, against 1 percent.
  • Stopping treatment because of side effects or death: 4 percent on 4 mg, 12 percent on 9 mg and 8 percent on 12 mg, against 5 percent on placebo.

The TRIUMPH-2 authors reported that deaths occurred in both the retatrutide and placebo groups (two, three and one on 4, 9 and 12 mg, and one on placebo) and that the investigators judged all of them unrelated to the study drug. They described the overall safety profile as generally consistent with other medicines that act on the GLP-1 receptor. For TRIUMPH-1 the report says only that the most common adverse events were gastrointestinal, so the figures above come from the diabetes trial and may differ in people without diabetes.

The phase 2 trial added two further points. The gut side effects were dose related, mostly mild to moderate, and partly reduced by a lower starting dose (2 mg rather than 4 mg). Heart rate rose in a dose-dependent way, peaked at 24 weeks and then declined. Our guide to why GLP-1 doses start low explains the stepping-up design.

Beyond weight

TRIUMPH-1 also looked at two conditions in subgroups. Among people with knee osteoarthritis, knee pain scores fell by 3.2, 3.5 and 3.6 points on 4, 9 and 12 mg, against 1.9 on placebo. Among people with obstructive sleep apnoea, breathing interruptions fell by 22.9, 34.3 and 31.7 events an hour, against 9.9 on placebo. These were measured in subgroups (574 people with knee osteoarthritis and 243 with sleep apnoea), so treat them as a sign of what researchers are testing, not as a treatment claim.

What the trials cannot tell you

  • The right dose for any person. The trials report group averages, and participants were followed by study clinicians.
  • Whether a vial from any supplier matches its label. The trials used pharmaceutical-grade product of known strength. See how to read a certificate of analysis.
  • Long-term safety beyond 80 weeks.
  • Regulatory status in South Africa. We do not have a verified source on whether retatrutide is registered here, so check with the regulator or a pharmacist.

Our retatrutide is sold for research use only and is not a registered medicine, so none of the doses above is a recommendation. For how it compares with the other GLP-1 compounds, see retatrutide vs tirzepatide vs semaglutide and our retatrutide guide.

Questions people ask

What are the side effects of retatrutide?

In the phase 3 TRIUMPH-2 trial the most common were gut related: diarrhoea in 27 to 34 percent and nausea in 14 to 28 percent, against 13 and 8 percent on placebo. Low blood pressure and an unusual skin sensation (dysesthesia) were also more frequent.

What doses were used in the retatrutide trials?

The phase 3 trials tested 4, 9 and 12 mg once a week for 80 weeks, and the phase 2 trial tested 1, 4, 8 and 12 mg for 48 weeks. In the phase 2 trial, doses were stepped up from a 2 mg or 4 mg start. They are trial doses, not recommendations.

How much weight did people lose on retatrutide?

In TRIUMPH-1, average loss at 80 weeks was 17.6, 23.7 and 25.0 percent on 4, 9 and 12 mg, against 3.9 percent on placebo. In TRIUMPH-2, in people with type 2 diabetes, it was 11.9, 16.8 and 18.8 percent against 5.1 percent.

Does a higher retatrutide dose cause more side effects?

Generally yes for the gut. In the phase 2 trial the gut side effects were dose related, and in TRIUMPH-2 nausea rose with each dose step. A lower starting dose reduced them.

Is retatrutide approved?

We do not have a verified source on its current regulatory status in South Africa or elsewhere. Check with the regulator or a pharmacist. Our products are sold for research use only.

Is retatrutide the same as tirzepatide?

No. Tirzepatide acts on two hormone receptors (GIP and GLP-1) and retatrutide on three (GIP, GLP-1 and glucagon). They are different molecules with different trial results.

Sources

  1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514-526.
  2. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med 2026;395:1781-1793.
  3. Bellido V, le Roux CW, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet 2026;408:1455-1472.

This article is for educational purposes only and is not medical advice. The compounds we supply are sold for research use only and are not registered medicines. Our guide to whether peptides are legal in South Africa explains what that means. Sources were checked on 16 November 2026, and new studies may have appeared since.

Next, read retatrutide half-life or how to get more from retatrutide.